Coverage for Weight Loss Medications Weight loss medications can be a valuable tool in helping individuals achieve their weight loss goals
doi:10.3803/EnM.2024.1942 Lilly Investor Relations, News Release: Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine, May 11, 2025
Participants on tirzepatide experienced an average weight loss of 20.2%, while those on semaglutide lost an average of 13.7%
This question concerns patients and clinicians as semaglutide (Ozempic, Wegovy) becomes increasingly prescribed for type 2 diabetes and weight management
1,2 Second Natures real-world data confirm that both medications achieve clinically significant weight loss for the vast majority of users: 95% with Mounjaro and 83% with Wegovy achieved at least 10% weight loss in our programme
To be clear, Wegovy itself hasnt been shown to have any direct impact on your reproductive system or your menstrual cycle, but that doesnt mean theres no connection between Wegovy and period changes at all
)
